FDA Clears Oral Wegovy Pill, First GLP1 Tablet for Obesity

The U.S. Food and Drug Administration approved Wegovy pill, a once daily 25 milligram oral semaglutide tablet, for use in adults with obesity or adults with overweight who have weight related medical conditions, Novo Nordisk announced on December 22, 2025. The approval covers use alongside a reduced calorie diet and increased physical activity to produce and maintain weight loss, and it includes an indication for reduction in the risk of major adverse cardiovascular events, often abbreviated MACE.

The decision was grounded in late stage clinical data, including the pivotal OASIS 4 trial published in the New England Journal of Medicine in 2025. The trial reported robust weight loss with the 25 milligram tablet, showing a mean weight reduction of about 16.6 percent. Company materials and regulatory filings described efficacy that is comparable to the injectable Wegovy formulation, which transformed obesity treatment when it launched in 2021.

Novo Nordisk said the pill represents a new option for patients who prefer an oral regimen. Dave Moore, executive vice president of U.S. Operations at Novo Nordisk, said the pill "will help patients who may have not sought or accepted treatment before." Mike Doustdar, president and chief executive officer of Novo Nordisk, declared "The pill is here," and described the once daily oral option as capable of helping patients "lose as much weight as the original Wegovy injection."

Safety data for the tablet reflected a familiar profile for GLP1 therapies. The most common adverse events were gastrointestinal in nature, including nausea, diarrhea and vomiting. Regulators and clinicians will be watching post approval data and real world experience as prescribing expands beyond the tightly controlled conditions of a clinical trial.

Novo Nordisk told investors and partners it expects to begin commercial distribution in the United States in early January 2026. The company has also submitted the oral semaglutide 25 milligram indication to the European Medicines Agency and to other regulators. Distribution plans discussed in trade outlets include partnerships with providers and consumer programs, a move that could broaden reach but also complicate equitable access depending on coverage details.

The pill will enter a competitive field. Other companies are developing oral GLP1 candidates, including Eli Lilly with orforglipron, and a new oral option could accelerate demand for obesity treatments. That surge poses policy challenges. Clinicians and public health experts warn that without clear insurance coverage rules, patient assistance programs, and safeguards against unequal access, advances in therapy risk worsening existing disparities in obesity related health outcomes.

Public health advocates say the approval underscores the need for coordinated policy responses. Insurers, federal and state programs, and employers will face pressure to determine coverage quickly. Health systems serving low income communities and rural areas will need funding and training to integrate new medication pathways into comprehensive weight management services that include diet, activity and behavioral care.

As the Wegovy pill moves toward U.S. shelves, physicians, patients and policymakers will be testing whether an oral option delivers not only greater choice, but also fairer access to effective obesity care.